Lake Street Capital began coverage on shares of OptimizeRx Corp. (OTCMKTS:OPRX) in a research report sent to investors on Monday morning, The Fly reports. The firm issued a buy rating on the technology company’s stock.
Separately, ValuEngine raised shares of OptimizeRx Corp. from a sell rating to a hold rating in a report on Monday, August 14th.
OptimizeRx Corp. (OTCMKTS:OPRX) last released its quarterly earnings results on Thursday, November 2nd. The technology company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). OptimizeRx Corp. had a negative net margin of 20.24% and a negative return on equity of 25.08%.
ILLEGAL ACTIVITY NOTICE: “OptimizeRx Corp. (OPRX) Research Coverage Started at Lake Street Capital” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.com-unik.info/2017/11/03/optimizerx-corp-oprx-research-coverage-started-at-lake-street-capital.html.
About OptimizeRx Corp.
OptimizeRx Corporation is a technology solutions company. The Company focuses on the healthcare industry. The Company connects patients, physicians and pharmaceutical manufacturers through technology. The Company’s solutions provide pharmaceutical manufacturers a direct to physician channel for communicating and promoting products.
What are top analysts saying about OptimizeRx Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for OptimizeRx Corp. and related companies.